When I’m asked about the most promising areas of stem cell clinical research, cell therapy for type I diabetes is near the top including work by a biotech called ViaCyte. Other firms are in the mix too, boosting the overall odds of success in the coming decade. It’s really that promising even though there are …
ViaCyte purchase puts Vertex in driver’s seat on stem cells for diabetes Read More »
Some unproven stem cell clinics like one called Giostar have multiple locations sprouting up. To me the concern with that spreading is the potential of multiplying risks to consumers. It can be hard to get a clear take on what these clinics are doing too. What’s in this article What is Giostar? | Giostar review | …
Giostar stem cell clinic chain review, red flags, & lawsuit Read More »
I’ve had concerns about an American unproven clinic firm called R3 Stem Cell for many years. They sell unproven stem cell-related “treatments” via dozens of affiliated locations. I put quotes around treatments because in my view there is no good evidence here for claims of treating numerous serious illnesses. The goal of today’s post is …
Fact-checking troubling R3 Stem Cell clinic chain Read More »
A few people in the stem cell field keep arguing that adult pluripotent stem cells exist, including so-called “very small embryonic-like stem cells” or VSEL stem cells. These days the supposed cells are called VSELs or V-cells too. Only a handful of researchers have ever been able to report finding and studying these cells. Others …
The regular emails and phone calls I get from patients asking questions about stem cell therapy are a powerful reminder of the fact that research in our field can be very personal. Sometimes individuals who receive experimental stem cell therapy (or other cell therapies) and seem to have a positive outcome can end up becoming …
How much promise is there today for stem cell therapy for heart disease? Where do things stand with the clinical research? Patients regularly ask me these kinds of questions. The goal of today’s post is to update you on where things stand. What’s in this post Stem Cell Therapy | Clinical Trials | Delivery of …
Stem cell therapy for heart disease: what you need to know Read More »
I am in the unique position of being a stem cell scientist who has no commercial interest in selling therapies so I can be impartial on giving patients and consumers guidance. In today’s post I give an overview of stem cell therapy and provide an expert, unbiased guide to navigating this area. This post is …
Updated patients guide to stem cell therapy for 2024 Read More »
About 1 million people are living with multiple sclerosis in the U.S. alone with millions of other cases around the world so a huge effort has gone into trying to find new approaches to the disease including stem cells for MS. We’ll start our weekly recommended reads by talking about a new paper on MS …
Stem cells for MS & other weekly reads: CRISPR, COVID & a bat cave, Huntington’s Read More »
As long as I’ve been writing The Niche as a professor here at UC Davis School of Medicine, people have been asking me about stem cell therapy for COPD. There is a lot of misinformation out there in this space. Let’s clear things up as to where the biomedical science stands today in late 2023 …
A quick review of the publicly-traded stem cell stocks I’ve been following in 2021 finds mostly discouraging news, but a few firms relatively outperformed the other publically-traded biotechs. One had some great news today. In this post, I’m doing a brief overview of how things went this year in the regenerative medicine space. I’m going …
2021 scorecard for stem cell stocks: REGN, VCEL, CCEL, LCTX did best Read More »